Group 1 - The core business of the company is focused on addressing diseases caused by mitochondrial dysfunction, utilizing NAD+ in areas such as cardiovascular diseases, neurodegenerative diseases, reproductive health, and aging [1] - The flagship commercial drug of the company is Enadi (injectable coenzyme I), alongside other products including Qianrongmei, Tianshu, injectable nitroprusside, and 16 generic drugs covering four major therapeutic areas [1] - As of January 16, 2026, the company has 20 drugs in the production stage [1] Group 2 - The market size for mitochondrial medicine products in China is expected to grow rapidly, projected to increase from 17.9 billion RMB in 2024 to 308.1 billion RMB by 2035, with a compound annual growth rate of 29.5% [1]
康诺生物递表港交所 国投证券国际为独家保荐人
Zheng Quan Shi Bao Wang·2026-01-26 01:47